Jae-Yong Kwak

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 5

Top Venues

Nature communications

Cancers

Chonbuk National University Medical School

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Chonbuk National University Medical School

South Korea

Professor :: Internal Medicine

Publications

Changhee Park, Ho Sup Lee, Byung Soo Kim, Won-Sik Lee, Young Rok Do, Jae-Yong Kwak, Ho-Jin Shin, Sung-Yong Kim, Jun Ho Yi, Sung-Nam Lim, Jeong-Ok Lee, Deok Hwan Yang, Hun Jang, Byoungsan Choi, Jiwoo Lim, Choong Hyun Sun, Ja Min Byun, Sung Soo Yoon, Youngil Koh
Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial. Nature communications 15 (1) (2024)
Changhee Park, Ho Sup Lee, Byung Soo Kim, Won-Sik Lee, Young Rok Do, Jae-Yong Kwak, Ho-Jin Shin, Sung-Yong Kim, Jun Ho Yi, Sung-Nam Lim, Jeong-Ok Lee, Deok Hwan Yang, Hun Jang, Byoungsan Choi, Jiwoo Lim, Choong Hyun Sun, Ja Min Byun, Sung Soo Yoon, Youngil Koh
Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial. Nature communications 15 (1) (2024)
Changhee Park, Ho Sup Lee, Byung Soo Kim, Won-Sik Lee, Young Rok Do, Jae-Yong Kwak, Ho-Jin Shin, Sung-Yong Kim, Jun Ho Yi, Sung-Nam Lim, Jeong-Ok Lee, Deok Hwan Yang, Hun Jang, Byoungsan Choi, Jiwoo Lim, Choong Hyun Sun, Ja Min Byun, Sung Soo Yoon, Youngil Koh
Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial. Nature communications 15 (1) (2024)
Changhee Park, Ho Sup Lee, Byung Soo Kim, Won-Sik Lee, Young Rok Do, Jae-Yong Kwak, Ho-Jin Shin, Sung-Yong Kim, Jun Ho Yi, Sung-Nam Lim, Jeong-Ok Lee, Deok Hwan Yang, Hun Jang, Byoungsan Choi, Jiwoo Lim, Choong Hyun Sun, Ja Min Byun, Sung Soo Yoon, Youngil Koh
Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial. Nature communications 15 (1) (2024)
Ho-Young Yhim, Dok Hyun Yoon, Seok Jin Kim, Deok-Hwan Yang, Hyeon-Seok Eom, Kyoung Ha Kim, Yong Park, Jin Seok Kim, Hyo Jung Kim, Cheolwon Suh, Won Seog Kim, Jae-Yong Kwak
First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial. Cancers 12 (8) (2020)

Jae-Yong Kwak.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Jae-Yong Kwak